Invasive cerebral small vessel function assessment in HTRA1-related cerebral small vessel disease including CARASIL

Open-label trial of acetazolamide in Cerebral Small Vessel Disease (CSVD) and Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) (2 arms), sponsored by No. Primary endpoint: Change in cerebral blood flow reactivity under acetazolamide stress at 6 months. Started Jul 2023; status: completed.